CAPR vs. MOR, CPRX, MLTX, MRUS, ARWR, HCM, EWTX, MIRM, AMRX, and GMTX
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include MorphoSys (MOR), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics vs.
MorphoSys (NASDAQ:MOR) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends.
Capricor Therapeutics received 333 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 63.59% of users gave Capricor Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
In the previous week, Capricor Therapeutics had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Capricor Therapeutics and 0 mentions for MorphoSys. Capricor Therapeutics' average media sentiment score of 0.70 beat MorphoSys' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.
MorphoSys currently has a consensus price target of $18.25, suggesting a potential downside of 3.74%. Capricor Therapeutics has a consensus price target of $34.50, suggesting a potential upside of 129.92%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than MorphoSys.
Capricor Therapeutics has lower revenue, but higher earnings than MorphoSys. Capricor Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 4.08, indicating that its share price is 308% more volatile than the S&P 500.
18.4% of MorphoSys shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 12.0% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Capricor Therapeutics has a net margin of -146.86% compared to MorphoSys' net margin of -226.79%. Capricor Therapeutics' return on equity of -112.95% beat MorphoSys' return on equity.
Summary
Capricor Therapeutics beats MorphoSys on 15 of the 18 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CAPR Stock Alerts